Rectal cancer neoadjuvant treatment in elderly patients

Anticancer Research

Volumn 26, Issue 5 B, 2006, Pages 3913-3923

  Pasetto, Lara Maria ^a   Friso, Maria Luisa ^a   Pucciarelli, Salvatore ^a   Basso, Umberto ^a   Falci, Cristina ^a   Bortolami, Alberto ^a   Toppan, Paola ^a   Agostini, Marco ^a   Rugge, Massimo ^a   Serpentini, Samantha ^a   Nitti, Donato ^a   Monfardini, Silvio ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Elderly; Neoadjuvant chemotherapy; Rectal cancer

Indexed keywords

FLUOROURACIL; OXALIPLATIN;

ADJUVANT THERAPY; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMORBIDITY; CONSTIPATION; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; FATIGUE; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; INCIDENCE; LEUKOPENIA; MALE; MORBIDITY; MUCOSA INFLAMMATION; NAUSEA; PATIENT COMPLIANCE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROCTITIS; RADIATION DOSE; RECTUM CANCER; RETROSPECTIVE STUDY; SEX DIFFERENCE; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

AGED; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; MALE; RECTAL NEOPLASMS;

EID: 33750736989     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics 1999. Cancer J Clin 49: 8-31, 1999.
2. Walter LC and Corvinsky KE: Cancer screening in elderly patients: a framework for individualized decision making. JAMA 285: 2750-2756, 2001.
3. Jessup JM, McGinnis LS, Steele GD, Menck HR and Winchester DP: The National Cancer Data Base. Report on colon cancer. Cancer 78: 918-926, 1996.
4. Kohne CH, Grothey A, Bokemeyer C, Bontke N and Aapro M: Chemotherapy in elderly patients with colorectal cancer. Ann Oncol 12: 435-442, 2001.
5. Rodel C, Grabenbauer GG, Shick C, Papadopoulos T, Hohenberger W and Sauer R: Preoperative radiation with concurrent 5Fluorouracil for locally-advanced T4 primary rectal cancer. Strahlenther Onkol 176: 161-167, 2000.
6. Videtic GM, Fisher BJ, Perera FE, Bauman GS, Kocha WI, Taylor M, Vincent MD, Plewes EA, Engel CJ and Stitt LW: Preoperative radiation with concurrent 5-fluorouracil continuous infusion for locally advanced unresectable rectal cancer. Int J Radiat Oncol Biol Phys 42(2): 319-324, 1998.
7. Chan AK, Wong AO, Langevin J, Jenken D, Heine J, Buie D and Johnson DR: Preoperative CT and pelvic radiation for tethered or fixed rectal cancer: a phase II dose escalation study. Int J Radiat Oncol Biol Phys 48(3): 843-856, 2000.
8. Grann A, Feng C, Wong D, Saltz L, Paty PP, Guillem JG, Cohen AM and Minsky BD: Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 49: 987-995, 2001.
9. Valentini V, Coco C, Cellini N, Picciocchi A, Fares MC, Rosetto ME, Mantini G, Morganti AG, Barbaro B, Cogliandolo S, Nuzzo G, Tedesco M, Ambesi-Impiombato F, Cosimelli M and Rotman M: Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, sphincter preservation in three consecutive studies. Int J Radiat Oncol Biol Phys 51: 371-383, 2001.
10. Moertel CG, Childs DS, Reitemeier RJ, Colby MY Jr and Holbrook MA: Combined 5FU and super voltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2: 865-867, 1969.
11. Rominger CJ, Gelber RD, Gunderson LL and Conner N: Radiation therapy alone or in combination with CT in the treatment of residual or inoperable carcinoma of the rectum and recto sigmoid or pelvic recurrence following colorectal surgery. Radiation Therapy Oncology Group Study. Am J Clin Oncol 8: 118-127, 1985.
12. Overgaard M, Bertelsen K, Dalmark M, Gadeberg CC, von der Maase H, Overgaard J and Sell A: A randomised feasibility study evaluating the effect of radiotherapy alone or combined with 5FU in the treatment of locally recurrent or inoperable colorectal carcinomas. Acta Oncol 32: 547-553, 1993.
13. Desch CE, Benson AB 3rd, Smith TJ, Flynn PJ, Krause C, Loprinzi CL, Minsky BD, Petrelli NJ, Pfister DG and Somerfield MR: Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol 17(4): 1312, 1999.
14. Roh MS, Petrelli N, Wieand S, Colangelo L, Smith R, Mamounas E, Hyams D and Wolmark N: Phase III randomised trial of preoperative versus postoperative multimodality therapy in patients with carcinoma of the rectum. Proc Am Soc Clin Oncol 20: 123a (abs 490), 2001.
15. Sauer R, Fietkau R, Wittekind C, Rodel C, Martus P, Hohenberger W, Tschmelitsch J, Sabitzer H, Karstens JH, Becker H, Hess C and Raab R: German Rectal Cancer Group. Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94. Colorectal Dis 5(5): 406-415, 2003.
16. Paty PB, Enker WE, Cohen AM, Minsky BD and Friedlander-Klar H: Long-term functional results of coloanal anastomosis for rectal cancer. Am J Surg 167: 90-95, 1994.
17. Minsky BD, Cohen AM, Kemeny N, Enker WE, Kelsen DP, Saltz L and Frankel J: The efficacy of preoperative 5Fluorouracil, high dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. Cancer 71(11): 3486-3492, 1993.
18. Bosset JF, Pavy JJ, Hamers HP, Horiot JC, Fabri MC, Rougier P, Eschwege F and Schraub S: Determination of the optimal dose of 5Fluorouracil when combined with low dose D,L-leucovorin and irradiation in rectal cancer: results of three consecutive phase II studies. EORTC Radiotherapy Group. Eur J Cancer 29(10): 1406-1410, 1993.
19. Marsh RD, Chu NM, Vauthey JN, Mendenhall WM, Lauwers GY, Bewsher C and Copeland EM: Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5fluorouracil infusion and radiation therapy. Cancer 78(2): 217-225, 1996.
20. Mohiuddin M, Regine Wf, John WJ, Hagihara PF, McGrath PC, Kenady DE and Marks G: Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for pathological complete response. Int Radiat Oncol Biol Phys 46(4): 883-888, 2000.
21. Streit M, Jaehde U, Stremetzne S, Ridwelski K, Kerz H, Strohbach F, Hohenberger P, Zwiebel FM, Hebart H, Bothig R, Kairies M, Zillig D, Schuchmann S, Warnecke S, Thiel E and Kreuser ED: Five days continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen. Ann Oncol 8(11): 163-165, 1997.
22. Hartmann JT, Kohne CH, Schmoll HJ, Daikeler T, Kanz L and Bokemeyer C: Is continuous 24-hour infusion of 5-fluorouracil plus high dose folinic-acid effective in patients with progressive or recurrent colorectal cancer? A phase II study. Oncology 55(4): 320-325, 1998.
23. Grobovsky L, Kaplon M, Krozser-Hamati A and Karnard A: Features of cancer in frail elderly patients (pts) (85 years of age). Proc Am Soc Clin Oncol 18: 139 (abstr 2469), 2000.
24. Trimble EL, Carter CL, Cain D, Freidlin B, Ungerleider RS and Friedman MA: Representation of older patients in cancer treatment trials. Cancer 74(suppl 7): 2208-2214, 1994.
25. Lichtman SM and Skirvin JA: Pharmacology of antineoplastic agents in older cancer patients. Oncology (Huntingt) 14: 1743-1755, 2000.
26. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, Mulsant B and Reynolds CF 3rd: Rating chronic medical illness burden in gero-psychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 41: 237-248, 1992.
27. Common Terminology Criteria for Adverse Events. Version 3.0 (CTCAE), December 12, 2003.
28. Enker EW, Thaler TH, Cranor LM and Polyak T: Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 181: 335-346, 1995.
29. Kaplan EL and Meier P: Non parametric estimation for incomplete observation. J Am Stat Assoc 53: 457-481, 1958.
30. Popescu RA, Norman A, Ross PJ, Parikh B and Cunningham D: Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17(8): 2412-2418, 1999.
31. Chiara S, Nobile MT, Vincenti M, Lionetto R, Gozza A, Barzacchi MC, Sanguineti O, Repetto L and Rosso R: Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 42(4): 336-340, 1998.
32. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G and Meropol NJ: Age and sex are independent predictors of 5-FU toxicity. Analysis of a large scale phase III trial. Cancer 75: 11-17, 1995.
33. Jirillo A, Paris MK, Rossi E and Monfardini S: Elderly cancer patients observed during one year in a division of medical oncology. IV Meeting of International Society of Geriatric Oncology (SIOG), abs 20, 2003.
34. Gomez H, Mas L, Casanova L, Pen DL, Santillana S, Valdivia S, Otero J, Rodriguez W, Carracedo C and Vallejos C: Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte- macrophage colony-stimulating factor: identification of two age subgroups with differing haematologic toxicity. J Clin Oncol 16: 2352-2358, 1998.
35. Lyman GH, Kuderer NM and Balducci L: Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients. Current Opinion Haematol 9: 207-214, 2002.
36. Repetto L, Biganzoli L, Koehne CH, Luebbe AS, Soubeyran P, Tjan-Heijnen VC and Aapro MS: EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 39(16): 2264-2272, 2003.
37. Crawford J, Dale DC and Lyman GH: Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100(2): 228-237, 2004.
38. Lyman GH, Kuderer N, Agboola O and Balducci L: Evidence-based use of colony-stimulating factors in elderly cancer patients. Cancer Control 10(6): 487-499, 2003.
39. Stipa F, Lucandri G, Ferri M, Casula G and Ziparo V: Local excision of rectal cancer with transanal endoscopic microsurgery (TEM). Anticancer Res 24(2C): 1167-1172, 2004.
40. Grann A, Minsky BD, Cohen AM, Saltz L, Guillem JG, Paty PB, Kelsen DP, Kemeny N, Ilson D and Bass-Loeb J: Preliminary results of preoperative 5FU, low-dose leucovorin, and concurrent radiation therapy for resectable T3 rectal cancer. Dis Colon Rectum 40: 515-522, 1997.
41. Pucciarelli S, Friso ML, Toppan P, Fornasiero A, Carnio S, Marchiori E and Lise M: Preoperative combined radiotherapy and chemotherapy for middle and lower rectal cancer: preliminary results. Ann Surg Oncol 7(1): 38-44, 2000.
42. Minsky BD, Cohen AM, Kemeny N, Enker WE, Kelsen DP, Saltz L and Frankel J: The efficacy of preoperative 5Fluorouracil, high dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. Cancer 71(11): 3486-3492, 1993.
43. Schaffer M, Thoma M, Wilkowski R, Schaffer P and Duhmke E: Radiochemotherapy as a preoperative treatment for advanced rectal cancer. Evaluation of down-staging and morbidity. Onkologie 25(4): 352-356, 2002.
44. Chen ET, Mohiuddin M, Brodovsky H, Fishbein G and Markus G: Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation. Int Radiat Oncol Biol Phys 30(1): 169-175, 1994.
45. Janjan NA, Khoo VS, Abbruzzese J, Pazdur R, Dubrow R, Cleary KR, Allen PK, Lynch PM, Glober G, Wolff R, Rich TA and Skibber J: Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson cancer Center experience. Int Radiat Oncol Biol Phys 44(5): 1027-1038, 1999.
46. Ngan SY, Burmeister BH, Fisher R, Rischin D, Schache DJ, Kneebone A, MacKay JR, Joseph D, Bell A and Goldstein D: Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a phase II trial for the trans-Tasman Radiation Oncology Group. Int Radiat Oncol Biol Phys 50(4): 883-887, 2001.
47. Mehta VK, Poen J, Ford J, Edelstein PS, Vierra M, Bastidas AJ, Young H and Fisher G: Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer. Dis Colon Rectum 45(1): 143-144, 2002.
48. Buhmeida A, Ristamaki R, Lamlum H, Bendardaf R, Heikkila S, Collan Y, Syrjanen K and Pyrhonen S: Nuclear area is a prognostic determinant in advanced colorectal cancer. Anticancer Res 25(4): 3083-3088, 2005.
49. Bendardaf R, Lamlum H and Pyrhonen S: Prognostic and predictive molecular markers in colorectal carcinoma. Anticancer Res 24(4): 2519-2530, 2004.
50. Pasetto LM, Jirillo A, Iadicicco G, Rossi E, Paris MK and Monfardini S: FOLFOX versus FOLFIRI: a comparison of regimens in the treatment of colorectal cancer metastases. Anticancer Res 25(1B): 563-576, 2005.
51. Pucciarelli S, Toppan P, Friso ML, Russo V, Pasetto L, Urso E, Marino F, Ambrosi A and Lise M: Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. Diseases Colon and Rectum 47(11): 1798-1807, 2004.
52. Sauer R, Fietkau R, Wittekind C, Rodel C, Martus P, Hohenberger W, Tschmelitsch J, Sabitzer H, Karstens JH, Becker H, Hess C and Raab R: German Rectal Cancer Group. Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94. Colorectal Dis 5(5): 406-415, 2003.
53. Reerink O, Mulder NH, Verschueren RC, Wiggers T, Szabo BG and Hospers GA: Addition of oxaliplatin to neo-adjuvant radiochemotherapy for irresectable rectal cancer, a phase I study. Anticancer Res 25(1B): 629-633, 2005.
54. Laudani A, Gebbia V, Leonardi V, Savio G, Borsellino N, Cusimano MP, Calabria C, Stefano R and Agostara B: Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma. Anticancer Res 24(2C): 1139-1142, 2004.
55. Chiara S, Nobile MT, Gozza A, Taveggia P, Heouaine A, Pastrone I, Percivale PL, Lionetto R, Sanguineti O and Rosso R: Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer. Anticancer Res 24(1): 355-360, 2004.
56. Aschele C, Friso ML, Pucciarelli S, Sartor L, Lonardi S, De Salvo G, Fabris G, Da Dalt G, Ranzato R, Bruttocao A, Neri D, Finco C and Monfardini S: A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Proc Am Soc Clin Oncol abs 527, 2002.